Studies targeting the regulator of PI3K, PTEN—whose loss is common in medulloblastoma—have shown innate resistance to SHH inhibitors in PTEN null medulloblastomas compared to PTEN wild-type medulloblastoma [23]. This evidence concerns the gene SHH and medulloblastoma.